{"groups":[{"description":"Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.","id":"FG000","title":"Multiple Myeloma (MM) Participants"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"No relapse/refractoriness(last 6 months)"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Not participated/met inclusion criteria"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"282"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"276"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with a diagnosis of multiple myeloma with symptomatic relapse and/or refractory disease were observed to collect the retrospective data on Day 1.","recruitmentDetails":"Participants took part in the study at 30 investigative sites in Spain from 26 July 2017 to 30 January 2019."}